Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

We compared the efficacy and the safety of a carboplatin plus etoposide regimen (CE) vs split doses of cisplatin plus etoposide (SPE) in elderly or poor-risk patients with extensive disease small-cell lung cancer (ED-SCLC). Eligibility criteria included: untreated ED-SCLC; age ⩾70 and performance st...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamoto, H, Watanabe, K, Kunikane, H, Yokoyama, A, Kudoh, S, Asakawa, T, Shibata, T, Kunitoh, H, Tamura, T, Saijo, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360311/
https://www.ncbi.nlm.nih.gov/pubmed/17579629
http://dx.doi.org/10.1038/sj.bjc.6603810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360311/
https://www.ncbi.nlm.nih.gov/pubmed/17579629
http://dx.doi.org/10.1038/sj.bjc.6603810

Ejemplares similares